Evaluation of blood glucose and serum lipids lowring effects of teneligliptin in patients with type 2 diabetes mellitus

Evaluation of blood glucose and serum lipids lowring effects of teneligliptin in patients with type 2 diabetes mellitus - Effects of teneligliptin on blood glucose and serum lipids profile

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012206

Enrollment

Registered

2013-11-05

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes mellitus

Interventions

teneligliptin 20mg per day for 12weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1:Patient with written concent for participation in this study 2:male and female 3:20 y.o or older 4:in- and out-patient

Exclusion criteria

Exclusion criteria: 1:contrandication to teneligliptin 2:Ineligible for this study

Design outcomes

Primary

Measure	Time frame
Blood pressure, LDL-c	—

Secondary

Measure	Time frame
HbA1c, blood glucose, u-Na, s-Na, s-Cr, u-Cr, NT-proBNP, IRI, ANP, sLDL, metylglyoxal, CRP	—

Countries

Japan

Contacts

Public ContactHiroyuki Ariyasu

Wakayama medical University First department of internal medicine

ariyasu@wakayama-med.ac.jp073(447)2300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026